TP53 and metastatic neoplasm: Analysis of initial clinical presentation revealed that patients retaining TP53 wild-type status after disease progression (TP53wtprogr) had featured a lower rate of metastatic disease at initial diagnosis than patients with TP53 mutations either at baseline (TP53mutbas, 67% vs. 91%, p = 0.034, Table 1) or at disease progression (TP53mutconv, 67% vs. 100%, p = 0.045, Table 1).